Of 11 guidance figures from Thermo Fisher Scientific's earnings releases that Stock Atlas has scored against the reported result, 3 came in above the guide, 4 in range and 4 below. It met or beat its own guidance 64% of the time.
| Period | Measure | Guided | Reported | Result |
|---|---|---|---|---|
| FY2025 | Free Cash Flow | $7.00B | $6.29B | below |
| FY2025 | Capital Expenditures | $1.40B to $1.70B | $1.52B | in range |
| FY2024 | Capital Expenditures | $1.30B to $1.50B | $1.40B | in range |
| FY2024 | Revenue | $42.40B to $43.30B | $42.88B | in range |
| FY2024 | Free Cash Flow | $6.50B to $7.00B | $7.27B | above |
| FY2023 | Revenue | $42.70B | $42.86B | above |
| FY2023 | Capital Expenditures | $1.70B | $1.48B | below |
| FY2023 | Free Cash Flow | $6.90B | $6.93B | above |
Above means the reported figure beat the top of the range, in range that it landed inside it or on a point guide, below that it missed. Every guide and revision, and screens across companies, are in the research platform.
Do companies beat their own guidance? The study · Back to Thermo Fisher Scientific financials
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Thermo Fisher Scientific (TMO) guidance record”, stockatlas.com/companies/TMO/guidance/, data as of 3 November 2026. Links to this page are welcome.
